Home » Stocks » CALA

Calithera Biosciences, Inc. (CALA)

Stock Price: $1.97 USD -0.03 (-1.50%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 148.10M
Revenue (ttm) n/a
Net Income (ttm) -86.09M
Shares Out 72.25M
EPS (ttm) -1.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $1.97
Previous Close $2.00
Change ($) -0.03
Change (%) -1.50%
Day's Open 2.00
Day's Range 1.96 - 2.02
Day's Volume 145,394
52-Week Range 1.78 - 6.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.

2 weeks ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecu...

1 month ago - GlobeNewsWire

SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering...

2 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molec...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molec...

3 months ago - GlobeNewsWire

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on March 16, 2021-- SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (N...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molec...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molec...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecu...

6 months ago - GlobeNewsWire

Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.

6 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecu...

6 months ago - GlobeNewsWire

Calithera Biosciences (NASDAQ: CALA) shares are trading lower after the company announced that its CANTATA study of Telaglenastat in Renal Cell Carcinoma did not achieve its primary endpoint. The compan...

Other stocks mentioned: BNGO
6 months ago - Benzinga

The company reported negative results from a clinical trial.

6 months ago - The Motley Fool

-- Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and emerging pipeline

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecu...

6 months ago - GlobeNewsWire

Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecu...

7 months ago - GlobeNewsWire

Calithera has an important near-term catalyst that could launch the company into a significant commercialization opportunity by mid-year 2021. The company also is running a triplet therapy trial that if...

8 months ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecu...

8 months ago - GlobeNewsWire

IL4I1 inhibitor shows immune-mediated anti-tumor activity IL4I1 inhibitor shows immune-mediated anti-tumor activity

8 months ago - GlobeNewsWire

Calithera Biosciences' (CALA) CEO Susan Molineaux on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

--Calithera to Provide Corporate Update via Conference Call and Webcast at2:00 p.m. PT on November 5, 2020-- SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (N...

8 months ago - GlobeNewsWire

Combination will be evaluated in patients with pancreatic ductal adenocarcinoma whose tumors have KRAS and CDKN2A mutations Combination will be evaluated in patients with pancreatic ductal adenocarcinom...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecu...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecu...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecu...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecu...

9 months ago - GlobeNewsWire

- Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard - of - care treatment in front-line setting among  patients with non-small cell lung cancer and a m...

10 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small mol...

10 months ago - GlobeNewsWire

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 10, 2020-- SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. ...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small mole...

1 year ago - GlobeNewsWire

Former Portola Pharmaceuticals President and Chief Executive Officer Brings Extensive Executive Leadership and Commercial Oncology Experience Former Portola Pharmaceuticals President and Chief Executive...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule dru...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mole...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mole...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molec...

1 year ago - GlobeNewsWire

Is (CALA) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Calithera Biosciences (CALA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Calithera (CALA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

-- KEAPSAKE is a Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations -- KEAPSAKE is a Phase 2 randomized...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mol...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mol...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mol...

1 year ago - GlobeNewsWire

Calithera (CALA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, April 14, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule dr...

1 year ago - GlobeNewsWire

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mole...

1 year ago - GlobeNewsWire

About CALA

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also dev... [Read more...]

Industry
Biotechnology
IPO Date
Oct 2, 2014
CEO
Susan Molineaux
Employees
92
Stock Exchange
NASDAQ
Ticker Symbol
CALA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CALA stock is "Buy." The 12-month stock price forecast is 5.00, which is an increase of 153.81% from the latest price.

Price Target
$5.00
(153.81% upside)
Analyst Consensus: Buy